

Initial Clinical Trials of hESC-Derived Oligodendrocyte Progenitor Cells in Subacute Spinal Cord Injury

> ISCoS Meeting September 14, 2016

Edward Wirth, III, M.D., Ph.D. Chief Medical Officer



## AST-OPC1: hESC-Derived Oligodendrocyte Progenitor Cells (OPCs)







### **AST-OPC1 (formerly GRNOPC1)**

- Cryopreserved Allogeneic Cell Population
- Derived from Human Embryonic Stem Cells (hESCs)
- Characterized Composition of Cells:
  - Oligodendrocyte progenitors
  - Neural progenitors
  - Infrequent mature neural cells and
  - Rare other characterized cell types
- Three identified functions
  - Produces neurotrophic factors
  - Induces remyelination
  - Induces vascularization
- "Off the shelf" administration
- First indication: spinal cord injury
- Potential line extensions in other neurodegenerative diseases

### AST-OPC1: Phase 1 Safety Study in Complete Thoracic SCI



### Summary of Phase 1 Thoracic Safety Study of AST-OPC1





4


# Evaluation of AST-OPC1 in Subacute Cervical SCI

# A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury

**Six Sites Currently Enrolling** 


ClinicalTrials.gov: NCT02302157





# AST-OPC1 Current Study Design

# Completed



Currently recruiting patients for both Cohorts 3 & 4

EF C




### **AST-OPC1** Injection Procedure

#### **Shepherd Center**





### Rush University




- Injections performed using a table-mounted syringe positioning device (SPD)
- Direct intra-parenchymal injection into the spinal cord lesion
- Single 50µL injection for both the 2M & 10M doses
- No intraoperative complications to date

### Upper Extremity Motor Recovery to Date

**Upper Extremity Motor Score (UEMS)** Avg. UEMS Change From Baseline 10-Cohort 1 (N=3) 8-Cohort 2 (N=5\*) 6-4 2 60 120 180 240 300 360 0 **Days Post-Injection** 

\* N=4 at Day 90 (fifth subject has only reached Day 60) Cohort 1: 2 million AST-OPC1 cells Cohort 2: 10 million AST-OPC1 cells





#### Motor Level Recovery at Day 90 Follow Up

## Upper Extremity Motor Score (UEMS) – Per Subject Data to Date

	2001	24	26		
			20	28	
Cohort 1	2101	20	24	27	
	2102	8	17	18	
Avg. time from SCI to AST-OPC1 Injection Cohort 1: 27 days Cohort 2: 28 days	Subject	Baseline	Day 90		
	2501	30	41	No correlation between degree of	
Cohort 2	2003	20	26		recovery and basel
	2301	24	38	UEMS	
	2502	32	39		
	2202	15		Has not reach	ed Day 90

BIOTHERAPEUTICS



- All subjects in Cohorts 1 & 2 have exhibited improved upper extremity motor scores (UEMS) relative to baseline
- The average UEMS improvement at Day 90 was 5.0 points in Cohort 1 (N=3) and 9.5 points in Cohort 2 (N=4)
- At 1-year of follow up, all subjects in Cohort 1 have improved one motor level on at least one side
- At Day 90 of follow up, 2 of 4 subjects in Cohort 2 have improved one motor level and 2 of 4 have improved two motor levels on at least one side (one patient has improved two motor levels on both sides)
- Cohort efficacy target of 2 of 5 patients improving two motor levels within 6-12 months post-administration has already been met, despite 4 patients only at Day 90 and 1 patient not yet even at Day 90



## Conclusions

- AST-OPC1 can be safely administered to patients in the subacute period after severe cervical SCI
- There have been no serious adverse events related to AST-OPC1, the injection procedure, or immunosuppression with low-dose tacrolimus
- A dose response effect on upper extremity motor recovery appears to be emerging by Day 90 of follow up, much earlier than we expected
- These data are early, but very encouraging; We look forward to the UEMS & motor level 6-month readouts in Cohort 2 in January 2017
- Concurrent enrollment of both AIS-B patients with 10M cells and AIS-A patients with 20M cells is in progress to further elucidate the dose response of OPC1



## Acknowledgments

#### Asterias

Jane Lebkowski

**Cathy Priest** 

Linda Jones

Maria Schaefer

Susy Chen

Anthony Davies

Jerrod Denham

Katy Spink

Nate Manley

Kevin Nishimoto

Naomi Kautz

AST-OPC1 Team



### The Trial Participants

Pre-Clinical Collaborators

Hans Keirstead

Gabriel Nistor

#### Committees

Steering Committee Data Monitoring Committee Radiology Committee Outcomes Committee

#### Funding

California Institute of Regenerative Medicine (CIRM)

#### **Clinical Investigators**

Richard Fessler James Young Don Leslie David Apple Gary Steinberg Steve McKenna Charles Liu Shekar Kurpad Eric Horn Jim Harrop Mary Schmidt Read David Chen

13